These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20628878)

  • 1. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
    Goff SL; Johnson LA; Black MA; Xu H; Zheng Z; Cohen CJ; Morgan RA; Rosenberg SA; Feldman SA
    Cancer Immunol Immunother; 2010 Oct; 59(10):1551-60. PubMed ID: 20628878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
    Hughes MS; Yu YY; Dudley ME; Zheng Z; Robbins PF; Li Y; Wunderlich J; Hawley RG; Moayeri M; Rosenberg SA; Morgan RA
    Hum Gene Ther; 2005 Apr; 16(4):457-72. PubMed ID: 15871677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
    Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
    Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
    Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
    Johnson LA; Heemskerk B; Powell DJ; Cohen CJ; Morgan RA; Dudley ME; Robbins PF; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6548-59. PubMed ID: 17056587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
    Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
    Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
    Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
    Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
    Pouw NM; Westerlaken EJ; Willemsen RA; Debets R
    J Gene Med; 2007 Jul; 9(7):561-70. PubMed ID: 17471588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
    Yang S; Cohen CJ; Peng PD; Zhao Y; Cassard L; Yu Z; Zheng Z; Jones S; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2008 Nov; 15(21):1411-23. PubMed ID: 18496571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
    Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
    Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
    Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
    J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
    Ray S; Chhabra A; Chakraborty NG; Hegde U; Dorsky DI; Chodon T; von Euw E; Comin-Anduix B; Koya RC; Ribas A; Economou JS; Rosenberg SA; Mukherji B;
    Clin Immunol; 2010 Sep; 136(3):338-47. PubMed ID: 20547105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen.
    Luo W; Zhang XB; Huang YT; Hao PP; Jiang ZM; Wen Q; Zhou MQ; Jin Q; Ma L
    J Mol Med (Berl); 2011 Sep; 89(9):903-13. PubMed ID: 21556811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.